Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on January 27, 2005, to announce its earnings for the quarter and year ended December 31, 2004. The report includes a press release detailing these results and clarifies that certain non-GAAP financial measures are presented to offer insights into the company's core business performance by excluding specific unusual or infrequent items. Investors should note that the company is providing adjustments for items such as the gain on Eyetech warrants, a make-whole payment for convertible debt redemption, an in-process R&D charge from the Triangle Pharmaceuticals acquisition, a vendor dispute settlement reimbursement, and impairment charges on long-lived assets. Management believes these adjustments provide a clearer view of ongoing results and trends relevant to the core business.
Key Highlights
- 1Gilead Sciences announced its financial results for the fourth quarter and full year ended December 31, 2004, via a press release filed with the 8-K.
- 2The company is presenting non-GAAP financial measures alongside GAAP results.
- 3These non-GAAP measures exclude several significant items impacting the reported financial statements.
- 4Key adjustments include a $20.6 million gain on Eyetech warrants and a $7.4 million make-whole payment for convertible debt redemption.
- 5Other excluded items consist of an $488.6 million in-process R&D charge from the Triangle Pharmaceuticals acquisition, a $13.2 million R&D reimbursement from a vendor settlement, and $10.9 million in impairment charges.
- 6Gilead's management uses these non-GAAP figures to monitor and evaluate ongoing results and believes they are useful for investors to understand core business trends.
- 7The 8-K filing primarily serves to furnish the earnings press release (Exhibit 99.1) as supplementary financial information.